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Summary. The discovery that the role human
papillomavirus (HPV) plays in the induction of human
cancer represents an important achievement in oncologic
research. It has taken on even greater importance since
the development of vaccines, which promise the hope of
preventing these cancers from ever occurring. Because
of these important implications, many have attempted to
determine a possible role for the virus in cancers of the
urinary bladder-an organ in close anatomic proximity to
the primary sites of HPV-induced neoplasia and one
which already has an established oncogenic infectious
agent in Schistosoma haematobium. Here we review the
current literature exploring this possible role in the most
common subtype of cancer of the urinary bladder,
urothelial carcinoma, and two much more rare histologic
subtypes that have well established roles for HPV-
induced neoplasia in other anatomic sites-squamous cell
carcinoma and adenocarcinoma. 
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Introduction
Viral induction of neoplasia has long been known to
be a major contributor to the overall burden of cancer on
the general population. It is estimated that up to 10-15%
of all human cancers are attributable to a viral agent
(Moore and Chang, 2010). These cancers are of
particular interest for a number of reasons. They allow
for a defined approach in determining the cellular and
genetic mechanisms involved in oncogenesis. Perhaps
more importantly, a known viral agent related to cancer
allows for selected screening, monitoring and, ideally,
vaccination against the causative agent. 
Despite this heavy burden placed on public health
due to viral-induced neoplasia, only seven human
viruses have been identified as definitive agents
involved in this process (Moore and Chang, 2010). The
first was the Epstein-Barr virus. Its discovery as an
etiologic agent of Burkitt lymphoma in 1964 began the
search for more cancers caused by viruses (Epstein et al.,
1964). Despite this vigorous search for more, only six
others have since been conclusively identified as human
cancer viruses: HTLV-1, HHV-8, MCV, HPV, HBV, and
HCV (Moore and Chang, 2010). Of these human cancer
viruses, there is perhaps none as important from a public
health perspective as HPV, the human papillomavirus.
The virus is said to contribute up to 10% of human
cancers worldwide (zur Hausen, 1996). The
identification of this virus as the etiologic agent of
cervical cancer (amongst others) has led to successful
public health screening and vaccination programs (zur
Hausen, 1989; Hendrix, 2008; Assmann and Sotlar,
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2011; Cobos et al., 2014). 
Because of the significant role HPV is known to
play in cervical, anogenital, and oropharyngeal cancers,
many have questioned whether the virus might play a
role in the development of urinary bladder cancers
(Bryant et al., 1991; Anwar et al., 1992; Lopez-Beltran
et al., 1996; Lopez-Beltran and Escudero, 1997; Tekin et
al., 1999; Weiss, 2008; Cobos et al., 2014). The
supposition is indeed logical-the urinary bladder has a
direct connection to the genital area through the urethra,
providing a natural passageway for viral migration. 
We investigated the evidence in the literature
relating to this question. In addition, this review was not
only limited to the most common form of bladder
malignancy, urothelial/transitional cell carcinoma, but
explored less common malignancies like squamous cell
carcinoma (SCC) and adenocarcinoma of the urinary
bladder, as those histological patterns are known to be
associated with HPV in other body sites. 
The Role of HPV in neoplasia
The mechanism of action for HPV-induced neoplasia
has been well studied. This action is primarily controlled
by two oncogenes, E6 and E7, which control the
production of oncoproteins of the same name (Cobos et
al., 2014). HPV E7 inactivates the cell cycle protein Rb1
(the product of the RB gene), a tumor suppressor protein
(zur Hausen, 1994; Munoz et al., 2003; Subhawong et
al., 2009). This disruption of the cell cycle is furthered
by the actions of HPV E6. This other oncoprotein serves
to degrade the important tumor suppressor protein, p53
(Scheffner et al., 1990). In this manner, HPV works to
disable two important tumor suppressor proteins within
the cell cycle which leads to the initiation of
tumorigenesis in patients where the virus is incorporated
into the DNA of the host cell. 
It is important to note that one of the effects of HPV
E7’s inactivation of Rb1 is the accumulation of the
tumor suppressor protein p16 (zur Hausen, 1994; Munoz
et al., 2003). The loss of Rb1 leads to a positive
feedback loop that causes p16 to accumulate; however,
the tumor suppressor effect is diminished or negated due
to the loss of Rb1. This increase in p16 has become
important as a diagnostic tool as immunohistochemical
staining for this protein serves as a “surrogate” marker
for HPV infection (Alexander et al., 2012, 2013, 2014). 
With the adoption of Pap testing for cervical cancer,
use of the cytomorphological effects has led to one of
the most successful public health initiatives of the last
century (Massad et al., 2009). As understanding of the
central role that certain strains of HPV play in the
development of cancer of the uterine cervix has evolved,
use of testing for the virus has served as an important
clinical adjunct to cytology in screening. This
understanding has led to the realization that only a few
strains of the many HPV strains are responsible for an
overwhelming majority of cancers. Because of this,
development of vaccines focusing on these particular
strains can have maximumclinical benefit without the
effort required in developing vaccines for the numerous
non-/less oncogenic strains of HPV. These vaccines are
now in clinical use and serve as the ultimate clinical goal
for all other oncogenic viruses (Cobos et al., 2014). With
the growing rates of other anogenital SCCs and the
increasing appreciation for HPV’s role in oropharyngeal
carcinoma, the reach of this accomplishment only
continues to grow. It is for this reason that such an
interest has been given to any possible role HPV may
play in cancers of the urinary bladder.
While much of the work has been focused on
urothelial carcinoma due to its commonality, exploration
into the role HPV might play in other less common
malignancies of the urinary bladder have been explored.
For the purpose of this review, we analyzed research that
has been conducted on urothelial carcinoma, SCC, and
adenocarcinoma of the urinary bladder. 
HPV in urothelial carcinoma of the urinary bladder
Cancers of the bladder are responsible for up to 6%
of all cancers in men and as many as 2% of cancers in
women, with urothelial carcinoma representing the
overwhelming majority of these (Silverberg, 1987). With
the knowledge that infection with Schistosoma
haematobium (bilharziasis) significantly increases the
risk of urinary bladder cancer, consideration of other
infectious etiologies has been strong (Malone et al.,
1987). Amongst the most intensely considered and
researched candidates has been HPV. Despite the amount
of work that has been done to fully elucidate this
possibility, significant controversy still remains as to the
etiologic nature of HPV with regards to urothelial
carcinoma in the urinary bladder (Griffiths and Mellon,
2000; Gutierrez et al., 2006).
Ever since HPV was reported in one of 10 bladder
tumors, researchers have been working to more
definitively prove an association between the virus and
cancer of the urinary bladder (Kitamura et al., 1988). A
number of studies have since detected HPV in at least a
subset of the cases analyzed (Bryant et al., 1991; Kerley
et al., 1991; Anwar et al., 1992; Chetsanga et al., 1992;
Furihata et al., 1993; Agliano et al., 1994; Maloney et
al., 1994; Kamel et al., 1995; Kim and Kim, 1995;
Lopez-Beltran et al., 1996; Chan et al., 1997). The types
and prevalence of infection in these cases varied
dramatically. Of those studies that showed a strong
presence of HPV in urinary bladder tumors, work from
Shigehara et al. provided some of the most convincing
evidence that HPV may play an etiological role in
urothelial carcinoma in the bladder. In a large study
involving 117 patients, 15% of the samples were found
to have HPV present (Shigehara et al., 2013). These
consisted primarily of the known oncologic HPV types
16, 18 and 33. Interestingly, HPV infection was found to
be far more common in low grade tumors (38% of grade
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1 tumors) and in those occurring in younger (<60 years)
patients. The authors posited that HPV might play an
etiologic role primarily in low grade tumors occurring in
younger patients. 
Despite the number of studies that have shown the
presence of HPV in urothelial carcinoma in the bladder,
the results are far from conclusive. A number of studies
have failed to show the presence of HPV in any of the
cases evaluated (Knowles, 1992; Saltzstein et al., 1993;
Sinclair et al., 1993; Chang et al., 1994; Sano et al.,
1995; Boucher and Anderson, 1997; Lu et al., 1997;
Aynaud et al., 1998). Many of these investigations have
included a large patient subset as well. Ben Selma et al.
investigated a total of 125 cases; 119 were urothelial
carcinoma, and found no evidence of HPV in any case
(Ben Selma et al., 2010). The work conducted by Chang
et al. looked at 108 cases and failed to detect any HPV
(Chang et al., 1994). An investigation by the group of
Youshya et al. looked at 78 cases of urothelial carcinoma
and also failed to detect any evidence of HPV infection
(Youshya et al., 2005).
Significant controversy to any role the virus plays in
the etiology of urothelial carcinoma persists-and for
good reason. In addition to the number of studies that
fail to show any evidence of HPV infection whatsoever,
even in those that do, many show only a very small
prevalence of the virus in cases examined. Questions
remain as to why this significant variability exists. Many
of these studies utilize different methods of detection:
PCR, IHC, southern blot, etc. It does not appear,
however, that any of the modalities can be specifically
targeted for being the “culprit.” Each of these modalities
can be seen to find HPV and not detect it in other
studies, so it appears that the testing method is not
entirety to blame. It may be that there is significant
variability within populations as to infection status with
the virus and the ease with which it is detected in
examined samples. What may be needed is a study that
looks at HPV infection status in urinary bladder tissue
samples in a population of people without cancer to
determine if a there is a baseline infection rate within the
population. The current evidence certainly fails to
conclusively implicate HPV as an etiologic agent for
urothelial carcinoma in the urinary bladder. 
HPV in squamous cell carcinoma of the urinary
bladder
SCC is the most common histologic type of cancer
associated with HPV. This association in the uterine
cervix has been mentioned many times already, but
SCCs of the anogenital region in general (anal, penile
and vulvar) also feature HPV as either a predominant or
significant contributor to their etiology (Keating et al.,
2001; Klaes et al., 2002; Agoff et al., 2003; Benevolo et
al., 2006; Horn et al., 2006; Dehn et al., 2007; Doxtader
and Katzenstein, 2012). Recently, a significant amount
of interest has been given to the role HPV plays in SCC
of the oropharynx. As smoking rates have declined in
developed countries, the contribution that HPV plays in
oropharyngeal SCC will continue to grow and, likely,
become the predominant etiologic agent of
oropharyngeal SCC. This discovery has further validated
the potential benefits that vaccination for HPV may have
on the population as a whole and increase the push to
find other human cancers that may be attributable to
HPV. 
The role of HPV in SCC of the urinary bladder has
been quite controversial. Much of this is due to to the
rarity of this malignancy. While SCC of the urinary
bladder may represent up to 75% of all bladder cancers
in areas where bilharzial infections are endemic, SCC
only represents 3-5% of all urinary bladder cancers
worldwide (Kantor et al., 1988; Mostafa et al., 1999;
Dahm and Gschwend, 2003; Shokeir, 2004; Kassouf et
al., 2007; Lagwinski et al., 2007). In two small studies
performed by Guo et al. and Westenend et al., no cases
of HPV were detected in the 32 collective cases
reviewed (Westenend et al., 2001; Guo et al., 2009). A
larger, more recent, study from Alexander et al. was
unable to find any evidence of HPV in 42 cases.
Interestingly, Alexander et al. also performed the same
analysis on 27 cases of urothelial carcinoma with
squamous differentiation, a morphologically similar
entity to pure SCC of the urinary bladder. Their results
showed no evidence of HPV in this entity that presents
as a diagnostic dilemma to SCC in the urinary bladder
(Alexander et al., 2012). These results correspond to
results reported on urothelial carcinoma with squamous
differentiation from Blochin et al. (2012). 
In all three of the studies on HPV in SCC of the
urinary bladder cited, all used HPV in situ hybridization
(ISH) as the primary method of detection. Research done
on a wide spectrum of urinary bladder cancers by Ben
Selma et al. used PCR to detect the presence of HPV.
Though only five of the 125 cases reviewed were SCC
of the urinary bladder, no evidence of HPV was found
by this method (Ben Selma et al., 2010). In the large
study from Shigehara et al. mentioned previously, no
HPV DNA was found in any of their cases of SCC of the
urinary bladder either. Despite having 11 cases, only 4
were eligible for their study and limited the yield of their
results with regards to SCC as these lacked statistical
significance (Shigehara et al., 2011). The analysis
performed by Alexander et al. also used p16
immunostaining to determine if the marker correlated
with HPV-ISH results, as it does in the uterine cervix
and oropharynx (Alexander et al., 2012). This was not
found to be the case as a number of cases showed
intense staining with p16 and no HPV positivity by ISH-
further concluding that p16 should not be interpreted as
a surrogate marker for HPV status in the urinary bladder. 
Though the evidence is limited, the published
literature examining a potential role for HPV in SCC of
the urinary bladder indicates that the virus does not play
a role in the tumorigenesis of this cancer. 
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HPV in primary adenocarcinoma of the urinary
bladder
Much like SCC of the urinary bladder, primary
adenocarcinoma of the urinary bladder is also quite rare.
And also like SCC of the urinary bladder, the
malignancy is more common in endemic areas of
bilharziasis (el-Mekresh et al., 1998; Zaghloul et al.,
2006). Despite this, primary adenocarcinoma of the
urinary bladder only accounts for up to 2% of all bladder
malignancies (Dahm and Gschwend, 2003; Ploeg et al.,
2009). The rarity of the disease is further compounded
by diagnostic challenges presented by morphology. In
many cases, primary adenocarcinoma of the urinary
bladder is indistinguishable by morphology from
adenocarcinomas arising from other body sites,
particularly the colon. Due to the much higher incidence
of these other adenocarcinomas, all studies must also
fully exclude the possibility that the tumor being
examined is of true urinary bladder origin and does not
represent invasive/metastatic disease. 
Due to these challenges, only one significant
publication was identified in the literature that rigorously
evaluated the possible etiological nature of HPV on
primary adenocarcinoma of the urinary bladder. A study
performed by Alexander et al. on 36 cases of clinically
confirmed cases of primary adenocarcinoma of the
urinary bladder failed to identify the presence of HPV in
any of the examined cases (Alexander et al., 2014). The
authors of the study employed HPV-ISH as their means
of detecting the virus, using both low-risk and high-risk
kits. As HPV is known to affect p16 and p53, these cell
cycle proteins were also evaluated to determine any
possible connection with HPV infection. Both markers
showed strong reactivity in a number of cases, but did
not show any correlation between each other and
obviously no correlation with the non-present HPV
(Alexander et al., 2014). In the large study on bladder
carcinoma by Shigehara et al., one of the six cases
evaluated for primary adenocarcinoma of the urinary
bladder was found to have HPV DNA present by PCR
(Shigehara et al., 2011); however, the limited number of
specimens sampled prevented any significant
conclusions being drawn from the data.
Though significant difficulties exist to performing
studies on this entity, the limited evidence available
suggests it is unlikely that HPV plays a significant role
in the tumorigenesis of adenocarcinoma in the urinary
bladder, but additional studies are encouraged to further
evaluate this possibility. 
There is no question that HPV plays a significant
role in the development of human cancers. The
successful efforts at vaccination against the virus,
thereby preventing the development of cancer, have only
made identifying a potential role for HPV in other
cancers that much more important from a public health
perspective. The urinary bladder’s proximity to the
anogenital region and its known association with another
oncogenic infectious agent, Schistosoma haematobium,
present it as a natural target for exploring this possibility. 
This review focused on three tumors in the urinary
bladder that represent the overwhelming amount of
cancers within the organ: urothelial carcinoma, SCC, and
adenocarcinoma. Of these, urothelial carcinoma makes
up the substantial majority of cases. While many have
reported HPV present in the tumors evaluated,
substantial evidence to indicate an etiologic role is not
present, with a number of reports entirely lacking any
presence of the virus. SCC and primary adenocarcinoma
of the urinary bladder are much rarer tumors and studies
are accordingly limited. These two tumors are of
particular interest, however, because they represent the
histologic subtypes most commonly associated with
HPV-induced neoplasia-particularly SCC. Current
evidence in the published literature fails to show any
strong association between the virus and these tumors.
This assertion is hindered by the size of the studies, but
the rarity of the entities presents a serious logistical
problem in conducting larger studies. 
Conclusions
The published literature indicates that HPV is most
likely not an etiologic agent in the three urinary bladder
tumor types reviewed. Due to the significant nature HPV
plays at a public health level, further determination of a
possible role in the development of urinary bladder
tumors is likely indicated. This is particularly true for
urothelial carcinoma, where the most controversy for a
possible role exists, due to its higher prevalence. Larger
studies, controlling for geographical, demographic, and
cultural differences, along with standardized or multiple
testing modalities may be indicated to determine any
true etiologic nature of HPV in this setting. 
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